# Research Peptide FAQ — Ipamorelin, MOTS-c, Retatrutide — Saline Peptides

> Frequently asked questions about three Research Peptide Fundamentals compounds — ipamorelin, MOTS-c, and retatrutide — answered from the peer-reviewed literature, with citations.

Direct, citation-anchored answers to the questions readers most often bring to these three research peptides.

## What is ipamorelin?

Ipamorelin is a synthetic five-amino-acid peptide (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates the ghrelin receptor (GHS-R1a) on the pituitary gland, triggering a short pulse of growth hormone release. First characterized in 1998, it distinguished itself from earlier growth-hormone-releasing peptides by not meaningfully raising cortisol or prolactin alongside GH [6]. It has never been approved as a drug for any indication and is sold only as a research chemical.

## What does ipamorelin do for you?

In the research literature, ipamorelin's documented effect is triggering a single pulse of growth hormone release from the pituitary gland, peaking about 40 minutes after dosing in human pharmacokinetic studies [4]. Beyond that core GH-axis effect, published research shows dose-dependent bone-growth changes in rats [5] and a reduction in chemotherapy-associated weight loss in a ferret model [1]. Its only human efficacy trial — in postoperative bowel-surgery patients — did not meet its primary endpoint [3], so no controlled human outcome beyond growth-hormone release itself has been demonstrated.

## What is ipamorelin peptide?

Ipamorelin is a pentapeptide, meaning it is built from five amino acids linked in a chain, with modified components (alpha-aminoisobutyric acid and two D-configured amino acids) that make it resistant to rapid enzymatic breakdown. It was derived from an earlier compound, GHRP-1, by removing its central two amino acids. Pharmacologically, it is classified as a growth hormone secretagogue — a molecule that prompts the pituitary gland to release growth hormone — and specifically as a selective ghrelin-receptor (GHS-R1a) agonist [6].

## What are the risks of ipamorelin?

The clinical and preclinical literature documents several risk areas, though none has been directly tested in a long-term human ipamorelin study. These include a theoretical concern around active or recent malignancy, given growth hormone's role in stimulating IGF-1 [6]; a class-level chronic cardiovascular signal (myocardial injury) documented in a related, non-ipamorelin GHS-R1a agonist after 28 days of dosing in rats [2]; and the underlying fact that ipamorelin's entire controlled human dataset is limited to one short perioperative trial [3] and one acute pharmacokinetic study [4], meaning long-term human safety has not been established. Research-grade ipamorelin from unregulated suppliers also carries no pharmaceutical quality assurance for purity or sterility.

## What does the MOTS-c peptide do?

In laboratory and animal research, MOTS-c inhibits a metabolic pathway called the folate cycle, which activates AMPK — a cellular energy sensor — improving glucose uptake in skeletal muscle and helping prevent muscle atrophy in several mouse models [8][10]. Under cellular stress, it also moves into the cell nucleus and influences gene expression [12], and exogenous MOTS-c has improved physical performance measures in mice across a range of ages [11]. In humans, the strongest available data are observational: naturally circulating MOTS-c levels are associated with lower combined mortality and cardiovascular risk in a hemodialysis patient cohort [9] — an association, not a demonstrated effect of an administered dose.

## What are the negative side effects of MOTS-c?

No completed human interventional trial of MOTS-c has been published, so there is no clinical side-effect profile to report from a controlled human study. The documented concerns instead come from the compound's research and regulatory record: its entire efficacy evidence base is animal and cell-based, its human dosing and pharmacokinetics have never been established, its research-chemical supply is unregulated for purity and sterility, and a mitochondrial DNA variant associated with certain ancestries has been linked to a pro-diabetogenic response and altered exercise response to MOTS-c signaling, meaning population-level effects are unlikely to be uniform [10].

## Is MOTS-c legal to buy?

MOTS-c is not approved by the FDA or any other regulator for human use; it is sold by suppliers as a research chemical labeled for laboratory use only, which is a distinct legal category from an approved medicine or dietary supplement. It is also treated as a prohibited substance by anti-doping authorities in sport, meaning athletes subject to testing can face sanctions for its use regardless of how it was obtained. This desk does not sell, source, or recommend any supplier, and takes no position on any individual jurisdiction's specific research-chemical regulations.

## How often do you inject MOTS-c?

There is no established, clinically studied, or approved injection frequency for MOTS-c in humans, because no completed human interventional trial exists. Published mouse studies — the only interventional research available — have used daily subcutaneous dosing schedules over periods of days to weeks, but rodent dosing regimens do not translate directly to a human protocol, and this desk does not provide one.

## What does retatrutide do?

Retatrutide activates three hormone receptors simultaneously — GLP-1, GIP, and glucagon [14]. The GLP-1 and GIP receptors suppress appetite and enhance glucose-dependent insulin release, while the glucagon receptor adds increased energy expenditure through fat-tissue thermogenesis. In a 48-week Phase 2 obesity trial, the highest dose produced a mean 24.2% body-weight reduction, the largest Phase 2 figure reported for any incretin-class peptide to date [16]. It remains an investigational compound in Phase 3 trials, not an approved medicine.

## How does retatrutide work?

Retatrutide's GLP-1 and GIP receptor activity reduces appetite and improves glucose-dependent insulin secretion — the same core mechanism shared with other incretin-class peptides. Its distinguishing third arm, glucagon-receptor activation, is proposed to increase energy expenditure through fat-tissue thermogenesis and fatty-acid oxidation, working on the energy-burned side of the equation rather than only the calories-eaten side [13]. Cryo-EM structural work confirms retatrutide engages all three receptors, with distinctly different binding behavior at each one [14].

## How to reconstitute retatrutide?

Within its own clinical trials, retatrutide is formulated, reconstituted, and administered as a subcutaneous injection under pharmacy-controlled conditions specific to the trial protocol — procedures that are validated and monitored by the trial's clinical pharmacy rather than published as general-use instructions. Peptides of this general type are typically supplied as a lyophilized powder that requires reconstitution with a sterile diluent immediately before use in a controlled research setting, followed by refrigerated storage to limit degradation. Retatrutide obtained outside a registered clinical trial is not an approved or verified pharmaceutical product, so no validated reconstitution protocol applies to material from any other source.

## Is retatrutide FDA approved?

No. As of mid-2026, retatrutide has not been approved by the FDA or any other regulatory agency anywhere. It is an investigational compound in Phase 3 clinical trials (the TRIUMPH program), and every efficacy and safety figure currently available comes from completed Phase 1 and Phase 2 studies [13][16][17]. It is legally available only to participants enrolled in a registered clinical trial.

---

Saline Peptides is a literature desk on research-peptide fundamentals — reconstitution notes and citations, never a dose, a diagnosis, or a doorway to a supplier.